Loading company…
Nabriva Therapeutics develops antibiotics for serious infections caused by resistant bacteria.
Nabriva Therapeutics develops antibiotics for serious infections caused by antibiotic-resistant bacteria. Its products include treatments for bacterial skin infections and community-acquired pneumonia. Founded in 2006, the company is based in Vienna, Austria, and was at the Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in